Facebook
Twitter
LinkedIn
Forward
2025 Summit for Novel Therapeutics in Oncology & Precision Medicine in Cancer (STOP Cancer)
Overview
The Summit for Novel Therapeutics in Oncology & Precision Medicine in Cancer (STOP Cancer) is a multidisciplinary conference that brings together clinicians, scientists, researchers, and pharmaceutical industry experts in the field of oncology to provide and gain insight into recent advances in cancer science and medicine. The primary aim of the conference is to discuss recent advancements, challenges, and future directions in the areas of novel therapeutic agents and drug discovery, clinical trial design, molecular profiling, and precision oncology. STOP Cancer will highlight the latest in early phase research and interpretation and application of precision medicine.
Designation | Advance (Ends August 26, 2025 at 11:59 p.m. Pacific time) | Standard (Begins August 27, 2025 at 12:00 a.m. Pacific time) |
| MD, DO, PhD | $490 | $590 |
Allied Health (NP, PA, RN, PharmD, Fellows, Residents, Retired) | $275 | $375 |
| Industry** | $790 | $890 |
**Defined as anyone employed by a drug, device, or diagnostic company. We allow Industry Professionals to register for our conferences unless you are employed in a sales role with your company. Please note that we will accept a limited number of Industry Professionals (excluding sales) to each conference.
Refunds of 50% of the registration fee will be provided if you cancel up to 30 days before the Summit for Novel Therapeutics in Oncology & Precision Medicine in Cancer (STOP CANCER) commences. There are no refunds for cancellations within the 30-day window of the start of the event. To request a refund, please email info@horizoncme.com
Privacy Statement: For online registration, we take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline. In order to use this website, a user must first complete the registration form. During registration, a user is required to give certain information (such as name, email, mailing address, and payment information). This information is confidential and will only be used to contact you regarding your registration.
Please note: times are subject to change. Please check the syllabus for the most current version of the agenda upon arriving at the summit.
All Times Listed are for the Pacific Standard Time Zone
Thursday, September 25, 2025 | |
| 8:30am | TBA |
| 11:00am | Pre-Conference Activity |
| 5:00pm | Pre-Conference Registration Opens |
| 6:00pm | Industry Sponsored Dinner |
Friday, September 26, 2025 | |
| 7:00am | Check-in and Breakfast in Exhibit Hall |
| 8:00am | Horizon CME App Overview and CE Housekeeping |
| 8:10am | Welcome, Introductions, & CE Housekeeping |
| 8:15am | (01) The Daniel D. Von Hoff Keynote Lecture: TBA » TBA |
| 9:15am | Break | Refreshments in Exhibit Hall |
| Block One: Small Molecules and Targeted Therapy | |
| 9:40am | (02) Innovations in HER2 Targeted Therapy » TBA |
| 10:00am | (03) Clinical Advances in KRAS Targeting » TBA |
| 10:20am | (04) FGFR-targeted drugs » TBA |
| 10:40am | (05) Targeting MTAP loss, a Synthetic Lethality Opportunity Hidden at Plain Sight » TBA |
| 11:00am | (06) Q+A Panel and Discussion: Block One » Faculty for Sessions 02 - 05 |
| 11:20am | Gather for Lunch |
| 11:30am | Lunch |
| 12:20pm | Dessert - Refreshments in Exhibit Hall |
| Block Two: Novel Approaches to Immunotherapy | |
| 12:40pm | (07) New Oncolytic Viruses on the Horizon » TBA |
| 1:00pm | (08) The Emerging Landscape of Bispecifics in Drug Development » TBA |
| 1:20pm | (09) CAR-T Cell Targets in Solid Tumors and Enhanced CAR-T Cells » TBA |
| 1:40pm | (10) NK Cell Therapy as a New Frontier in Cancer Treatment » TBA |
| 2:00pm | (11) Novel Immunotherapy Targets and Combinations » TBA |
| 2:20pm | (12) Q+A Panel and Discussion: Block Two » Faculty for Sessions 07 - 11 |
| 2:40pm | Message from the Cancer Charities |
| 2:55pm | Break - Refreshments in the Exhibit Hall |
| 3:15pm | Poster Session |
| Block Three: Advances in Precision Oncology 2025 | |
| 4:05pm | (13) Lung Cancers » TBA |
| 4:25pm | (14) Breast Cancers » TBA |
| 4:45pm | (15) GI Cancers » TBA |
| 5:05pm | (16) GU Cancers » TBA |
| 5:25pm | (17) Q+A Panel and Discussion: Block Three » Faculty from Sessions 13 - 16 |
| 5:45pm | Networking Reception - Exhibit Hall |
Saturday, September 27, 2025 | |
| 7:00am | Check-in & Breakfast Available in Exhibit Hall |
| 7:10am | Breakfast Symposium- sponsored by TBA » TBA |
| 8:00am | Horizon CME App Overview and CE Housekeeping |
| 8:05am | Welcome and Introductions |
| Block Four: Biomarkers in Cancer | |
| 8:10am | (18) ctDNA Applications in Management of Advanced Disease Patients on Investigational Agents » TBA |
| 8:30am | (19) AI as a Predictive Model in Drug Targets » TBA |
| 8:50am | (20) Companion Diagnostic Development » TBA |
| 9:10am | (21) Comprehensive Profiling » TBA |
| 9:30am | (22) Q+A Panel and Discussion: Block Four » Faculty from Sessions 18 - 21 |
| 9:50am | Break - Refreshments in the Exhibit Hall |
| Block Five: Clinical Trial Methodology | |
| 10:30am | (23) Strategies for Patient enrollment » TBA |
| 10:50am | (24) Early Phase Clinical Design in the Future » TBA |
| 11:10am | (25) The Evolution of Agnostic Drug Approval: Where Are We Now? » TBA |
| 11:30am | (26) Conduct of Early Phase Trials/Role of Patient Advocacy » TBA |
| 11:50am | (27) Minority/Diversity Enrollment in Clinical Trials for Early Phase » TBA |
| 12:10pm | (28) Q+A Panel and Discussion: Block Five » Faculty from Sessions 23 - 27 |
| 12:30pm | Gather for Lunch |
| 12:40pm |
Buffet Lunch & Non-CME/CE Presentation Sponsored by TBA » TBA |
| 1:30pm | Dessert Break in Exhibit Hall |
| Block Six: ADC | |
| 1:50pm | (29) Pre-Clinical Considerations in ADC Development » TBA |
| 2:10pm | (30) Clinical Advances in ADC Development and Novel Payloads » TBA |
| 2:30pm | (31) Novel Combination Approaches for ADC Therapeutics » TBA |
| 2:50pm | Break - Refreshments in the Exhibit Hall |
| 3:10pm | (32) Novel ADC Targets in Solid Tumors » TBA |
| 3:30pm | (33) Toxicity Management Considerations with Current ADC Landscape » TBA |
| 3:50pm | (34) Q+A Panel and Discussion: Block Six » Faculty from Sessions 29 - 33 |
| 4:10pm | Closing Comments |
We want to ensure that your time at Summit for Novel Therapeutics in Oncology & Precision Medicine in Cancer is convenient and memorable. staying at our host hotel provides a hassle-free experience and puts you at the heart of the activity surrounding the conference.
Overnight Accommodations:
Room rates: TBA
Parking: TBA
Available Credit
- 9.25 ABIM Medical KnowledgeHorizon CME, Inc. designates this activity for a maximum of 9.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 9.25 ACPE PharmacyThe Washington State Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This conference is approved for up to 9.25 credit by the Washington State Pharmacy Association.
This activity is approved for up to 9.25 credit by the Washington State Pharmacy Association. ACPE#: 0130-9999-21--L01-P | Activity Type: Live| Start/End date: Fri, 09/26/2025 - 7:00am-Sat, 09/27/2025 - 4:10pm The Washington State Pharmacy Association (WSPA) is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. NOTE FOR PHARMACISTS: It is the responsibility of the pharmacist or pharmacy technician to provide the correct information [NABP eProfile ID and DOB (in MMDD format)] within the evaluation, in order to receive credit for participating in this CPE activity. Following the activity’s end date, there is a maximum of 60 days allowed to upload the CPE information to the CPE Monitor. WSPA will upload the CPE information to the CPE monitor 50 days after the activity - please check your CPE Monitor at this time to ensure the CPE is uploaded in your profile. If you encounter any CPE problems, please contact WSPA at 425- 228-7171 - 9.25 AMA PRA Category 1 Credit™Horizon CME designates this Live activity for a maximum of 9.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 9.25 ANCCThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 9.25 credit.
- 3.50 PharmacologyThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 3.50 credit.